NCT06974851

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity

Conditions

• Bstructive Sleep Apnea (OSA) and Obesity

Interventions

Type	Name	Description
DRUG	HRS9531	HRS9531
DRUG	HRS9531placebo	HRS9531placebo

Timeline

• Start date: 2025-07-25
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-05-16
• Last updated: 2025-11-17

Locations

1 site across 1 country: China